Log In
Print
BCIQ
Print
Print this Print this
 

Redectane, 124-Iodine-girentuximab (CA9-SCAN)

Also known as: WX-G250RIT

  Manage Alerts
Collapse Summary General Information
Company Wilex AG
DescriptionRadiolabeled WX-G250 antibody
Molecular Target Carbonic anhydrase IX (CAIX)
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose clear cell renal cell carcinoma (ccRCC)
Regulatory Designation

U.S. - Special Protocol Assessment (Diagnose clear cell renal cell carcinoma (ccRCC))

Partner

Ion Beam Applications S.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today